Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development
Journal article published in 2019 by
Marisa A. Fuse,
Christine T. Dinh,
Jeremie Vitte 
,
Joanna Kirkpatrick,
Thomas Mindos,
Stephani Klingeman Plati,
Juan I. Young,
Jie Huang,
Annemarie Carlstedt,
Maria Clara Franco,
Konstantin Brnjos,
Jackson Nagamoto,
Alejandra M. Petrilli,
Alicja J. Copik,
Julia N. Soulakova
and other authors.
,
Joanna Kirkpatrick,
Thomas Mindos,
Stephani Klingeman Plati,
Juan I. Young,
Jie Huang,
Annemarie Carlstedt,
Maria Clara Franco,
Konstantin Brnjos,
Jackson Nagamoto,
Alejandra M. Petrilli,
Alicja J. Copik,
Julia N. Soulakova
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 